Variables | LVRR (+) | LVRR (−) | p value |
---|---|---|---|
(n = 15) | (n = 29) | ||
Age (years) | 60 ± 11 | 58 ± 13 | 0.512 |
Men | 13 (87%) | 26 (89%) | 0.767 |
New York Heart Association class | |||
I – II | 11 | 24 | 0.207 |
III – IV | 5 | 5 | |
Diabetes mellitus | 4 (27%) | 3 (10%) | 0.206 |
Atrial fibrillation | 6 (40%) | 4 (14%) | 0.067 |
Nonsustained ventricular tachycardia | 6 (40%) | 11 (38%) | 0.894 |
Serum creatinine (mg/dl) | 0.87 ± 0.16 | 0.81 ± 0.25 | 0.406 |
Estimated glomerular filtration rate (ml min-1 1.73 m-2) | 80.3 ± 12.2 | 79.8 ± 12.1 | 0.738 |
Complete left bundle brunch brock | 2 (13%) | 6 (21%) | 0.549 |
QRS duration (ms) | 101 ± 14 | 111 ± 32 | 0.173 |
Follow-up periods (years) | 5.9 ± 3.2 | 4.4 ± 2.8 | 0.220 |
Pharmacological treatments | |||
β blockers | 15 (100%) | 29 (100%) | >0.99 |
Carvedilol | 13 (87%) | 24 (83%) | 0.737 |
Dose (mg/day) | 11.3 ± 4.8 | 10.8 ± 5.3 | 0.761 |
Metoprolol | 2 (13%) | 5 (17%) | 0.735 |
Dose (mg/day) | 60.0 ± 28.2 | 56.0 ± 21.9 | 0.879 |
Angiotensin converting enzyme inhibitors/angiotensin II receptor blockers | 12 / 3 (100%) | 24/5 (100%) | >0.99 |
Enalapril | 10 (67%) | 20 (69%) | 0.877 |
Dose (mg/day) | 5.2 ± 1.8 | 4.6 ± 0.9 | 0.318 |
Losartan | 2 (13%) | 3 (20%) | 0.767 |
Dose (mg/day) | 37.5 ± 17.7 | 41.7 ± 14.4 | 0.738 |
Loop diuretics | 13 (87%) | 27 (93%) | 0.596 |
Spironolactone | 7 (45%) | 15 (52%) | 0.751 |
Digitalis | 11 (73%)’ | 20 (67%) | 0.763 |
Amiodarone | 1 (7%) | 4 (14%) | 0.647 |